BYSI - BeyondSpring's manuscript on Plinabulin published in JAMA Oncology

JAMA Oncology, the American Medical Association’s peer-reviewedjournal published  BeyondSpring's ([[BYSI]] -0.3%) manuscript, titled 'Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer.'The manuscript analyzed company’s Phase 2 portion of its PROTECTIVE-1 randomized clinical trial, which consisted of four treatment arms and was conducted in 19 treatment centers in the U.S., China, Russia and Ukraine from April 2017 through March 2018.“The data presented demonstrates that Plinabulin – a novel, non-G-CSF small molecule with anticancer activity – has potent neutropenia prevention effects,” said Dr. Douglas Blayney, Principal Investigator of CIN program with Plinabulin.Press ReleasePreviously: BeyondSpring's Plinabulin effective in preventing life-threatening chemo-induced neutropenia (Sept. 24)

For further details see:

BeyondSpring's manuscript on Plinabulin published in JAMA Oncology